ClinicalTrials.gg
CompletedNCT00313170FINDER IIUpdated Jan 6, 2020Results posted

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

A Phase 2 interventional study of Fulvestrant in Advanced Breast Cancer and Metastatic Breast Cancer, sponsored by AstraZeneca. Completed at 35 sites in 8 countries. Open to female participants aged 45 Years to 130 Years. Per ClinicalTrials.gov, last updated 2020-01-06.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
45 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
35th of 94
144 · median 71
Started
2006
with 4 others
Phase 2
59 of 95
8 open now
Registered
21st of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 35th largest by enrollment of the 94 interventional ones that give a count, is one of 5 that started in 2006, is one of 59 in phase 2, and was the 21st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 45 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.

03

Conditions studied

  • Advanced Breast Cancer
  • Metastatic Breast Cancer

Keywords

  • oncology
  • cancer
  • breast cancer
04

Who can participate

Ages eligible
45 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor.
  • Requiring hormonal treatment.
  • women (woman who has stopped having menstrual periods)

Exclusion criteria

Exclusion Criteria:

  • Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced BC.
  • Treatment with more than one previous regimen of endocrine therapy for advanced BC.
  • An existing condition that prevents compliance.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    1

    Fulvestrant 250 mg (intramuscular injection 250 mg)

    Drug: Fulvestrant

  • Experimental
    2

    Fulvestrant 250 mg (+ 250 mg loading regimen)

    Drug: Fulvestrant

  • Experimental
    3

    Fulvestrant 500 mg (intramuscular injection 500 mg)

    Drug: Fulvestrant

Interventions

  • intramuscular injection 250 mg \& 500 mg

    Also known as: Faslodex, ZD9238

06

What researchers measure

Primary outcomes

  1. Objective Response (ORR)

    Objective response rate was defined as percentage of patients with either complete response (CR - disappearance of all target lesions) or partial response (PR - at least 30% decrease in the sum of diameters of target lesions). All patients were to be followed up every 12 weeks for progression, defined by response evaluation criteria in solid tumors (RECIST v1.1).

    Time frame: The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.

Secondary outcomes

  1. Time to Progression (TTP)

    Time from randomisation until objective disease progression or death (in the absence of objective progression) using the Kaplan-Meier method. RECIST tumor assessments were carried out every 12 weeks until progression.

    Time frame: The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.

  2. Duration of Response (DoR)

    DoR was defined as the time from date of first documentation of the response (CR or PR) until the date of disease progression or death from any cause.

    Time frame: The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.

  3. Clinical Benefit Rate (CBR)

    CBR was defined as the proportion of all randomised patients who had clinical benefit (response of CR, PR or SD\>=24 weeks.

    Time frame: The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.

  4. Pharmacokinetic Parameter: Mean Population Clearance, a Measure of the Efficiency With Which Fulvestrant is Eliminated From the Body

    A 2-compartment model with a 1st order absorption and 1st order elimination process was fitted to the fulvestrant concentration-time data. Relative standard error is reported for the mean.

    Time frame: Baseline to 12 weeks

  5. Pharmacokinetic Parameter: Mean Volume of Distribution at Steady State, a Measure of the Apparent Volume in the Body Into Which Fulvestrant Distributes

    A 2-compartment model with a 1st order absorption and 1st order elimination process was fitted to the fulvestrant concentration-time data. Relative standard error is reported for the mean. The mean estimate of volume of distribution at steady state was reported as the sum of V1/F and V2/F in the clinical study report.

    Time frame: Baseline to 12 weeks

07

Results

Posted Aug 29, 2011

Participant flow

Postmenopausal women with oestrogen receptor positive advanced breast cancer progressing or relapsing after previous endocrine therapy were randomised between 30th May 2006 and 30th November 2007

Participant flow — Overall Study
MilestoneFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
Started475146
Completed111714
Not completed363432
Withdrew: Death242
Withdrew: Adverse event120
Withdrew: Disease progression312627
Withdrew: Withdrawal by subject101
Withdrew: Incorrect enrollment021
Withdrew: Lost to follow-up001
Withdrew: Progression (investigators opinion)100

Outcome measures

PrimaryObjective Response (ORR)

Objective response rate was defined as percentage of patients with either complete response (CR - disappearance of all target lesions) or partial response (PR - at least 30% decrease in the sum of diameters of target lesions). All patients were to be followed up every 12 weeks for progression, defined by response evaluation criteria in solid tumors (RECIST v1.1).

Time frame:
The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.
Reported as:
Number · Percentage of patients
Objective Response (ORR)
Percentage of patientsFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
Objective Response (ORR)8.5 (2.4 to 20.4)5.9 (1.2 to 16.2)15.2 (6.3 to 28.9)
SecondaryTime to Progression (TTP)

Time from randomisation until objective disease progression or death (in the absence of objective progression) using the Kaplan-Meier method. RECIST tumor assessments were carried out every 12 weeks until progression.

Time frame:
The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.
Reported as:
Median · Days
Time to Progression (TTP)
DaysFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
Time to Progression (TTP)88 (79 to 260)172 (80 to 339)169 (82 to 477)
SecondaryDuration of Response (DoR)

DoR was defined as the time from date of first documentation of the response (CR or PR) until the date of disease progression or death from any cause.

Time frame:
The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.
Reported as:
Median · Days
Duration of Response (DoR)
DaysFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
Duration of Response (DoR)NA (NA to NA)NA (66 to NA)539 (539 to 539)
SecondaryClinical Benefit Rate (CBR)

CBR was defined as the proportion of all randomised patients who had clinical benefit (response of CR, PR or SD\>=24 weeks.

Time frame:
The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.
Reported as:
Number · Percentage of patients
Clinical Benefit Rate (CBR)
Percentage of patientsFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
Clinical Benefit Rate (CBR)31.9 (19.1 to 47.1)47.1 (32.9 to 61.5)47.8 (32.9 to 63.1)
SecondaryPharmacokinetic Parameter: Mean Population Clearance, a Measure of the Efficiency With Which Fulvestrant is Eliminated From the Body

A 2-compartment model with a 1st order absorption and 1st order elimination process was fitted to the fulvestrant concentration-time data. Relative standard error is reported for the mean.

Time frame:
Baseline to 12 weeks
Reported as:
Least squares mean · litres per hour
Pharmacokinetic Parameter: Mean Population Clearance, a Measure of the Efficiency With Which Fulvestrant is Eliminated From the Body
litres per hourFulvestrant
Pharmacokinetic Parameter: Mean Population Clearance, a Measure of the Efficiency With Which Fulvestrant is Eliminated From the Body31 ± 3.29
SecondaryPharmacokinetic Parameter: Mean Volume of Distribution at Steady State, a Measure of the Apparent Volume in the Body Into Which Fulvestrant Distributes

A 2-compartment model with a 1st order absorption and 1st order elimination process was fitted to the fulvestrant concentration-time data. Relative standard error is reported for the mean. The mean estimate of volume of distribution at steady state was reported as the sum of V1/F and V2/F in the clinical study report.

Time frame:
Baseline to 12 weeks
Reported as:
Least squares mean · Liters
Pharmacokinetic Parameter: Mean Volume of Distribution at Steady State, a Measure of the Apparent Volume in the Body Into Which Fulvestrant Distributes
LitersFulvestrant
V1/F20600 ± 3.67
V2/F35700 ± 27.8

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fulvestrant 250 mg2/47 (4.3%)4/47 (8.5%)36/47 (76.6%)
Fulvestrant 250 mg + Loading Dose4/50 (8%)9/50 (18%)35/50 (70%)
Fulvestrant 500 mg2/46 (4.3%)4/46 (8.7%)31/46 (67.4%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
Pleural EffusionRespiratory, thoracic and mediastinal disorders0/472/500/46
PainGeneral disorders0/470/501/46
PneumoniaInfections and infestations0/470/501/46
Hip FractureInjury, poisoning and procedural complications0/470/501/46
AmnesiaNervous system disorders0/470/501/46
Renal ColicRenal and urinary disorders0/470/501/46
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/471/501/46
Macular HoleEye disorders1/470/500/46
Meniscus LesionInjury, poisoning and procedural complications1/470/500/46
Ischaemic StrokeNervous system disorders1/470/500/46
Most frequent other events
Showing 10 of 34
Most frequent other events
EventFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
NauseaGastrointestinal disorders12/479/507/46
FatigueGeneral disorders4/4711/507/46
Hot FlushVascular disorders9/475/503/46
Back PainMusculoskeletal and connective tissue disorders5/478/507/46
ConstipationGastrointestinal disorders3/477/501/46
Injection Site PainGeneral disorders6/477/506/46
ArthralgiaMusculoskeletal and connective tissue disorders4/477/504/46
DiarrhoeaGastrointestinal disorders3/474/506/46
MyalgiaMusculoskeletal and connective tissue disorders6/471/502/46
CoughRespiratory, thoracic and mediastinal disorders6/476/504/46

Baseline characteristics

Age, Continuous
Age, Continuous(years)Fulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mgTotal
Mean63.7 ± 9.968.1 ± 9.965.5 ± 9.065.8 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Fulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mgTotal
Female475146144
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mgTotal
Caucasian455146142
Oriental (Japanese)1001
Oriental (Asian other than Chinese or Japanese)1001
08

Study locations

35 sites
  • Research Site
    Brussels, 1000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Wilrijk, 2610, Belgium
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Cambridge, Ontario N1R 3G2, Canada
  • Research Site
    London, Ontario N6A 4L6, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
  • Research Site
    Sault Ste. Marie, Ontario P6A 2C4, Canada
  • Research Site
    Toronto, Ontario M4C 3E7, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Quebec, G1S 4L8, Canada
  • Research Site
    Cheb, 350 02, Czechia
  • Research Site
    Jicin, 506 43, Czechia
  • Research Site
    Praha 4, 140 00, Czechia
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Brive, 19312, France
  • Research Site
    Clermont Ferrand cedex 01, 63011, France
  • Research Site
    Poitiers, 86000, France
  • Research Site
    Budapest, 1062, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Györ, 9024, Hungary
  • Research Site
    Szeged, 6720, Hungary
  • Research Site
    Tatabánya, 2800, Hungary
  • Research Site
    Bydgoszcz, 85-796, Poland
  • Research Site
    Gdańsk, 80-214, Poland
  • Research Site
    Gdańsk, 80-462, Poland
  • Research Site
    Kraków, 31-115, Poland
  • Research Site
    Olsztyn, 10-228, Poland
  • Research Site
    Bucharest, Romania
  • Research Site
    Bucuresti, Romania
  • Research Site
    Cluj Napoca, 40015, Romania
  • Research Site
    Istanbul, Turkey
09

References and documents

Publications

  • Pritchard KI, Rolski J, Papai Z, Mauriac L, Cardoso F, Chang J, Panasci L, Ianuli C, Kahan Z, Fukase K, Lindemann JP, Macpherson MP, Neven P. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat. 2010 Sep;123(2):453-61. doi: 10.1007/s10549-010-1022-9. Epub 2010 Jul 15. PubMed 20632084 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2006 to primary completion in Jun 2008, 24 months.

Results were first posted in Aug 2011, 3 years 2 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 24 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2006
First posted
Apr 12, 2006
StartActual
May 30, 2006
Primary completionActual
Jun 13, 2008
CompletionActual
Mar 13, 2019
Results first posted
Aug 29, 2011
Last update
Jan 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00313170
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 12, 2006
Start date
May 30, 2006
Primary completion
Jun 13, 2008
Completion
Mar 13, 2019
Results posted
Aug 29, 2011
Last update
Jan 6, 2020

Study contacts

AstraZeneca Breast Cancer Established Brands Team Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion